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Abstract Familial hypercholesterolemia (FH) is an autoso-
mal dominant genetic disorder that clinically leads to in-
creased low density lipoprotein-cholesterol (LDL-C) levels.
As a consequence, FH patients are at high risk for cardiovas-
cular disease (CVD). Mutations are found in genes coding for
the LDLR, apoB, and PCSK9, although FH cannot be ruled
out in the absence of a mutation in one of these genes. It is
pivotal to diagnose FH at an early age, since lipid lowering
results in a decreased risk of cardiovascular complications
especially if initiated early, but unfortunately FH is largely
underdiagnosed. While a number of clinical criteria are avail-
able, identification of a pathogenic mutation in any of the three
aforementioned genes is seen by many as a way to establish a
definitive diagnosis of FH. It should be remembered that clin-
ical treatment is based on LDL-C levels and not solely on
presence or absence of genetic mutations as LDL-C is what
drives risk. Traditionally, mutation detection has been done by
means of dideoxy sequencing. However, novel molecular test-
ing methods are gradually being introduced. These next gen-
eration sequencing-based methods are likely to be applied on
broader scale once their efficacy and effect on cost are being
established. Statins are the first-line therapy of choice for FH
patients as they have been proven to reduce CVD risk across a
range of conditions including hypercholesterolemia (though
not specifically tested in FH). However, in a significant pro-
portion of FH patients LDL-C goals are not met, despite the
use ofmaximal statin doses and additional lipid-lowering ther-
apies. This underlines the need for additional therapies, and
inhibition of PCSK9 and CETP is among the most promising
new therapeutic options. In this review, we aim to provide an
overview of the latest information about the definition, diag-
nosis, screening, and current and novel therapies for FH.
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Introduction
Familial hypercholesterolemia (FH), a common autosomal
dominant inherited disorder, is characterized by high plasma
levels of low density lipoprotein-cholesterol (LDL-C) and, as
a consequence, high risk for the premature development of
atherosclerosis and cardiovascular disease (CVD) [1]. The
pathological substrate of FH is related to the dysfunctional
uptake of LDL particles via its receptor and this can either
be caused by mutations in the genes encoding for the LDL
receptor (LDLR), apolipoprotein B (apoB), or pro-protein
convertase subtilisin/kexin 9 (PCSK9). It is important to diag-
nose FH at an early age in order to prevent vascular events.
The diagnosis is based on clinical parameters such as lipid
levels, presence of xanthomas, family history, and vascular
disease, and a definite diagnosis is based either on the identi-
fication of a pathogenic mutation in any of the three well-
established FH-causing genes or a probably score derived
from clinical characteristics [2]. It has also been postulated
that a polygenic form of FH is present in patients meeting
the clinical criteria for FH (i.e., according to the Dutch Lipid
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Criteria Score, Simon Broome Criteria) who do not carry a
mutation in one of these genes [3]. There is a wide range in the
lipid levels among patients with FH, and this is largely related
to the severity of the mutation and the specific gene; patients
carrying a mutation in the LDLR gene, for example, tend to
suffer from a more severe phenotype than APOB mutation
carriers [4]. The CVD outcome differs among heterozygous
carriers of FH mutations, who, in general, typically suffer
from CVD events in their fourth decade of life, while patients
suffering from homozygous FH, the much rarer form of FH,
might already have experienced serious cardiovascular com-
plications in the second decade of life or even in childhood
[5].
HMG-coenzyme reductase inhibitors (Bstatins^) are the
therapy of first choice in FH patients [6]. It is of note however
that both the magnitude of CVD risk in untreated FH patients,
as well as the CVD risk reduction of statins, is not well-
established as randomized controlled trials have not been con-
ducted in this regard. We aim to provide a comprehensive
overview of the pathophysiology, epidemiology, screening
programs as well as current and future therapies of FH.
Pathophysiology and Genetics
LDLR
FH is caused by a mutation in the gene encoding the LDLR in
more than 90 % of the molecular diagnosed cases, and this
mutation leads to absent or dysfunctional LDLR at the surface
of the hepatocytes [7]. As a consequence, hepatic uptake of
LDL-C is decreased which results in elevated plasma levels of
LDL-C [1]. The LDLR gene is located on the short arm of
chromosome 19, and to date, over 1700 mutations in the
LDLR gene have been described (http://www.ucl.ac.uk/ldlr/
Current/). Five different classes of LDLR mutations have
been identified, dependent on the effect on the phenotype.
Class 1 mutations are null mutations that result in no
detectable LDLR protein. In class 2 mutations, the transport
of the LDLR from the endoplasmic reticulum to the Golgi
apparatus is blocked completely (class 2a) or partially (class
2b). A class 3 mutation leads to expression of a non-functional
LDLR. Class 4 mutations result in LDL binding but the
LDLR-LDL complexes cannot be internalized, and in class
5 mutations, recycling of the LDLR is not efficient and there-
fore do not reach the cell surface [8].
APOB
In 5 % of the molecular-diagnosed FH cases, a pathogenic
mutation is found in the gene encoding for apoB and this
disease is also referred to as familial defective apoB [9]. The
impaired binding of LDL particles to the LDLR therefore
results in higher circulating LDL-C concentrations.
PCSK9
In 2003, gain-of-function mutations in a third gene, encoding
for PCSK9, were identified as a cause of FH [10]. PCSK9,
when forming a complex with the LDLR, is internalized by
modification of the LDLR confirmation and interferes with
LDLR recycling. This leads to LDLR degradation and there-
fore reduction of the amount of receptors available at the he-
patocyte surface to bind circulating LDL particles [10].
Homozygous FH
Patients suffering from homozygous FH (HoFH) are charac-
terized by severely elevated LDL-C levels (typically above
13 mmol/L), and due to this extreme dyslipidemia, patients
have been reported to suffer cardiovascular events in the first
decade of life [11]. The molecular defect can either be caused
by homozygosity or, more frequently, compound heterozy-
gosity for mutations predominantly in the LDLR gene.
Moreover, combined mutations in APOB and PCSK9 have
also been described (double heterozygotes) [11].
Epidemiology
Unfortunately, the number of individuals diagnosed with FH
in most countries is <1 %, except for countries where active
screening does take place such as in the Netherlands and
Norway where 71 and 43 % of the patients have been de-
scribed to be diagnosed [7]. These numbers, however, were
based on an estimated prevalence of heterozygous FH (HeFH)
of 1 in every 500 [12]. However, a recent study showed that
HeFH was present twice as often in a large Danish population
(1 per 200–250). In this study, Benn and co-workers applied
the Dutch Lipid Network Criteria to quantify the prevalence of
FH in the Copenhagen Heart Study, a prospective study com-
prising over 69,000 Caucasians of Danish descent. In this
cohort, 7.76 % were found to meet the Bprobable or definite
FH^ criteria using the Dutch Lipid Network criteria [13].
These numbers are very much in line with the numbers that
were found in the study of Sjouke et al. who used a genetic
approach focusing on a molecular diagnosis [14]. The data-
base of the nationwide molecular diagnostic center was used
to identify 49 HoFH patients. The Hardy-Weinberg equilibri-
um was used to calculate the prevalence, resulting in a prev-
alence of 1 in 4,180,597 for HoFH and 1 in 319 for HeFH. In
another study where large-scale exome sequencing was per-
formed, approximately 1 in 217 of the patients who were free
of CVD was found to carry a mutation in LDLR, whereas the
prevalence of mutations was 1 in 50 in those patients who
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suffered from a premature CVD event [15•]. This clearly
shows that the true prevalence of FH is probably in the order
of 1 in every 200 inhabitants, which would translate in a total
of approximately 4.5 million patients with FH in Europe and
presumably 35 million people globally. It is of note that re-
gional differences in the prevalence of FH has been described,
with higher prevalences in certain populations due to founder
effect, for example in South-Africa and Quebec [16].
Consequences and Clinical Hallmarks of Familial
Hypercholesterolemia
Due to impaired clearance, LDL-particles accumulate in the
arterial wall leading to an inflammatory response. The endo-
thelial tissue becomes damaged and atherosclerotic plaques
are formed [17]. Endothelial damage begins at a young age,
which was shown by studies by de Jongh and co-workers,
who measured endothelial function by means of flow-
mediated dilation (FMD) in children who were diagnosed
with HeFH and their non-affected brothers and sisters. It was
shown that endothelial function was already impaired in these
asymptomatic HeFH patients at the age of 9 to 18 years [18].
The extent of atherosclerosis is further enhanced by other risk
factors [19]. It is of note that some risk factors, such as ele-
vated levels of the proatherogenic lipoprotein (a) (Lp (a)), are
commonly observed in FH patients [20]. Moreover,
triglyceride-rich lipoprotein remnants might contribute to in-
creased CVD risk and premature atherosclerosis in FH [21].
Atherosclerotic plaques are predominantly found in the coro-
naries, peripheral arteries, and aortic valve [2]. Furthermore,
cholesterol can accumulate in the skin leading to xanthomas,
which are primarily observed in the tendons at the elbows,
hands, and Achilles. Cholesterol depositions are also found
around the eyes in the form of xanthelasmata or in the cornea,
where it can be observed as an arcus lipoides. The presence of
xanthoma is pathognomonic for FH and one of the diagnostic
criteria for FH [7]. In FH patients, presence of xanthomas are
associated with a threefold increased risk of CVD compared to
FH patients without xanthomas [22]. Xanthomas are more
frequently seen in HoFH, even at birth or during early child-
hood [11], but can also be seen in HeFH later in life.
How to Diagnose Familial Hypercholesterolemia
Clinical Versus Molecular Diagnosis
There are several diagnostic criteria to diagnose FH based on
different phenotypical and molecular scoring algorithms, and
the prediction based on these criteria sets do not differ to a
great deal [23]. The Dutch Lipid Network Criteria is widely
accepted and commonly used [24]. These can be used to
calculate a score predicting the likelihood of FH, whereas a
score higher than five makes the diagnosis probable (Table 1).
Other criteria that are used and internationally validated are
the Simon Broom system criteria [25], the MEDPED criteria
(Make Early Diagnosis to Prevent Early Death) [26], and the
Japanese criteria [27]. Secondary causes of hypercholesterol-
emia such as proteinuria, hypothyroidism, or medication must
be excluded [24].
Finding a pathogenic mutation in the LDLR, APOB, or
PCSK9 gene is considered to be the gold standard for diag-
nosing monogenic causes of FH. However, FH cannot be
ruled out in the absence of a known mutation being identified.
In fact, in a substantial number of cases, no monogenic defect
can be identified [28]. Reported mutation detection rates range
from 20 to 95 % [29–31]. It is possible that in these patients
mutations in hitherto unidentified FH genes are present. In line
with this assumption is the recent finding of mutations in
STAP1 in patients with FH [32]. Carriers of mutations in this
gene were characterized by an FH-like phenotype. Little is
known however about the role of STAP1 in lipid metabolism.
The gene does not seem to be expressed in tissue with an
Table 1 Dutch Lipid Clinic Network criteria for diagnosis of
heterozygous familial hypercholesterolemia
Group 1: family history Points
• First-degree relative with known premature coronary
heart disease (CHD) (<55 years for men; <60 years
for women)
1
• First-degree relative with known LDL cholesterol
95th percentile by age and gender for country
1
• First-degree relative with tendon xanthoma and/or
corneal arcus OR
2
• Child(ren) <18 years with LDL cholesterol >95th
percentile by age and gender for country
2
Group 2: clinical history
• Subject has premature CHD (<55 years for men;
< 60 years for women)
2
• Subject has premature cerebral or peripheral vascular
disease (<55 years for men; <60 years for women)
1
Group 3: physical examination
• Tendon xanthoma 6
• Corneal arcus in a person <45 years 4
Group 4: biochemical results (LDL cholesterol)
• >8.5 mmol/L (>325 mg/dL) 8
• 6.5–8.4 mmol/L (251–325 mg/dL) 5
• 5.0–6.4 mmol/L (191–250 mg/dL) 3
• 4.0–4.9 mmol/L (155–190 mg/dL) 1
Group 5: molecular genetic testing (DNA analysis)
• Causative mutation shown in the LDLR, APOB, or
PCSK9 genes
8
With the algorithm, a numerical score can be calculated which predicts
the change that a subject has FH. It is only possible to score once per
group. The highest applicable can be chosen. BDefinite FH^ >8 points,
BProbable FH^ 6–8 points, BPossible FH^ 3–5 points
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established role in LDL-metabolism, and clearly, the
unraveling of the effect of STAP1 mutations warrants further
studies. Identification of such novel BFH genes^might have a
huge impact on our understanding and treatment of dyslipid-
emia [33]. Alternatively, the FH phenotype might be due to a
number of relatively benign variations in a number of genes, a
so-called polygenic form of FH. This hypothesis was tested by
Talmud, Humphries and coworkers [3], who indeed showed
that the number of LDL-C increasing variations was higher in
FH patients in whom no monogenic form was identified com-
pared to controls. It should be emphasized, however, that the
LDL-C levels in these subjects were in general lower com-
pared to patients in whom a monogenic defect was identified
(LDL-C of 5.87 and 7.03 mmol/L, respectively, p=0.002) [3].
It is important to note that mode of inheritance of these SNPs
is not dominant, since the SNPs are located over the whole
genome [34]. Furthermore, it is unclear whether this is indeed
familial, as the former has implications for genetic screening
of relatives whereas non-Mendelian inheritance would not.
Screening for Familial Hypercholesterolemia
Because of the high prevalence of FH, a systemic approach in
screening is a legitimate strategy for public health. There are
several screenings methods for FH. In the Netherlands, cas-
cade screening has been exploited for over two decades. Upon
identification of the index case, family-directed cascade
screening s takes place. Index cases can, for example, be iden-
tified by opportunistic screening among patients with a
(family) history of a CVD event at a young age. Measuring
LDL-C levels in such patients should be performed on a rou-
tine basis and, while applying any of the clinical criteria met-
rics, this can be followed by DNA analysis [35]. When a
pathogenic mutation is found, cascade screening can take
place identifying the same mutation in first-degree relatives.
In the Netherlands, over 27,000 individuals have been diag-
nosed with FH by this method. Multiple studies have shown
that cascade screening is the most cost-effective screenings
strategy for FH [36, 37]. Although genetic testing has been
widely accepted as the gold standard for the diagnosis, mea-
suring LDL-C levels is obligatory since these levels tailor the
extent of therapy being prescribed [38]. It is of note that some
patients with pathogenic mutations do not show the expected
phenotype of elevated LDL-C levels [39], and given the fact
that the LDL-C rather than the mutation is the driver of the
CVD risk, any preventive therapy measure should be focused
on the clinical phenotype, rather than on the presence of a
molecular defect [40].
Another type of screening is universal screening, which
involves screening of all individuals in a certain category,
for example children of a certain age. So far, this only has
been introduced in Slovenia for children at the age of 5 [41].
Universal screening in the USA at 9 and 11 years has been
proposed, for example when vaccination takes place.
Recently, it has been proposed to consider universal screening
in patients under 20 years of age and preferable before puberty
[35]. Ideally, this screenings strategy would be integrated with
cascade screening afterwards, to maximize the detection rate
[42].
Molecular Diagnosis: New Detection Methods
Several molecular testing methods are being used to detect
mutations in any of the established FH genes, including
dideoxy sequencing, array-based sequencing (in case of a rel-
atively limited number of mutations in the population), or
denaturing high performance liquid chromatography
(DHPLC) and melting analysis [43]. For detection of large
insertions of deletions, multiplex probe amplification
(MLPA) is used [43]. The large disadvantage of the Sanger-
based sequence methods is that it is relatively time and labor
intensive and this problem is largely overcome by next gen-
eration sequencing (NGS) where multiple genes can be ana-
lyzed at once. NGS can produce billions of nucleotide reads
from a sample of one patient and is relatively inexpensive
[44]. NGS can either be used to perform whole genome se-
quencing (WGS), whole exome sequencing, or targeted
subgenome analysis [45], and with these techniques, causative
mutations have been identified in a number of patients with
monogenetic disease [44]. For FH, NGS has been used in a
number of laboratories with differences in success rates [46].
CVD Risk in FH
In the pre-statin era, patients were considered to be at a 100-
fold increased risk for coronary heart disease mortality when
aged 20–39 [25]. Statins were introduced in the 1990s and
numerous studies have shown that the lowering LDL-C levels
by statin therapy results in a reduction in cardiovascular mor-
tality and morbidity [47]. The effect of statins on CVD events
in FH patients, however, has not been well addressed. It is
widely considered that the aforementioned 100-fold increased
risk might be an overestimate. Several studies have been pub-
lished about the CVD risk in FH patients and the risk ratio
(RR) associated with FH range from 3 to 16 [13, 15•, 48].
Benn et al. (2010) used The Danish General Population to
estimate the risk of coronary artery disease (CAD) in probable
or definite FH using the Dutch Lipid Network criteria and
found that FH patients, who were not treated with lipid low-
ering therapy, were at 13-fold risk for CAD compared to non-
FH individuals [13].When using lipid-lowering therapy, com-
pared to non-FH subject, patients with FH were at a 10-fold
risk for CAD. In another study by Huijgen et al., patients with
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a pathogenic LDLRmutation had a shorter event-free survival
than their relatives who did not carry that mutation (HR 3.64,
95 % CI=3.24–4.08, P<0.001) [48]. In a recent study by Do
and co-workers, exome sequencing was performed in nearly
10,000 genomes of patients with myocardial infarction (MI) at
a young age, as well as controls. It was found that carriers of
non-synonymous mutations in the gene coding for the LDLR
were at 4.2-fold higher increased risk for MI. This risk was
even higher in carriers of an LDLR null mutation (13-fold
difference) [15•] (see Table 2 for an overview).
Current Therapy
In a number of international guidelines, different LDL-C tar-
gets for therapy in FH have been published over the last
5 years. The target for LDL-C varies in these guidelines and
ranges from a minimal 50 % reduction of plasma LDL-C to a
target LDL-c level below 2.5 or 1.8 mmol/L in FH patients
without or with sharply increased risk for CVD, respectively.
The recently published ESC/EAS guideline on FH recom-
mends an LDL-C target level below 2.5 mmol/L for adults,
below 1.8 mmol/L for adults with coronary heart disease
(CHD) or diabetes, and below 3.5 mmol/L for children.
Targets are the same for HeFH and HoFH, regardless of age
[7]. The Canadian Guidelines by the Canadian Society also
recommend target LDL-C based on different risk categories.
For patients with high risk (i.e., CAD, peripheral vascular
disease (PVD), atherosclerosis or diabetes) and moderate risk,
LDL-C target is <2 mmol/L; in the low risk category
(Framingham risk score <10 %), an LDL-C reduction of
>50 % is recommended [49]. However, the Framingham risk
score is not reliable in FH. The recently updated ACC/AHA
guidelines (USA) recommend a reduction of >50 % plasma
LDL-C levels, acknowledging the fact that no evidence is
available supporting a pre-defined target LDL-C level [6].
It is of note that statins, albeit their efficacy in lowering
LDL-C, are widely underused in FH patients [13].
Moreover, the LDL-C levels recommended by the EAS/ESC
are not met in over half of the FH patients using statins, even
in patients who are treated with maximal doses [50].
Statins
Statin therapy is the cornerstone in the treatment of patients
with FH. There is a large and robust amount of evidence
showing reduction in cardiovascular events by use of statins
[24, 47]. The effectiveness of statins is based up on up-
regulation of LDLR by inhibiting HMG-CoA reductase,
resulting in lower plasma LDL-C [21]. In their study,
Versmissen and colleagues specifically addressed the effect
of statins in patients with HeFH [51]. In this non-randomized,
retrospective study, it was shown that when treated with
statins before onset of CHD, there was a risk reduction of
76%.Moreover, the risk of myocardial infarction in this statin
treated group was similar to that in the general population. In
the EAS consensus paper of the EAS of Nordestgaard et al., it
is advised to start with a maximal potent statin dose in FH
patients, if tolerated [7]. In case LDL-C levels are not
achieved, adding ezetimibe, a cholesterol absorption inhibitor,
is advised [7].
In some HoFH patients, statins may be effective, although
the effects on plasma LDL-C levels are known to be relatively
modest [52], which is due to the severe deficiency in LDLR
function. Therapy of choice for HoFH patients is weekly
LDL-C apheresis [53]. If apheresis is not available, lomitapide
(oral microsomal triglyceride transfer protein (MTP) inhibitor)
or mipomersen (antisense apoB) can be given in addition to
statins to further lower LDL-c [35].
Ezetimibe
Addition of ezetimibe may be necessary to achieve LDL-C
targets. Due to reduced absorption of cholesterol in the bowel,
there is a compensatory increase in LDLR on hepatocytes and
consequently and 20 % reduction in LDL-C [5]. Ezetimibe
could also be prescribed as monotherapy for individuals who
are not able to tolerate statins, but is preferably given in com-
bination [54]. In the ENHANCE trial, treatment with a com-
bination of ezetimibe and simvastatin did not result in a sig-
nificant difference in intima-media thickness (cIMT) in
Table 2 Cardiovascular disease in FH
CVD risk
Simon Broome Register Group (1991) [25]
• Deaths from coronary disease
FH vs. non FH
SMR: 386
(95 % CI 210 to 639)
Benn et al. (2012) [13]
• CAD in FH vs. non FH (no lipid
lowering therapy)
OR: 13.2
(95 % CI 10.0–17.4)
• CAD in FH vs. non FH (with lipid
lowering therapy)
OR: 10.3
(95 % CI 7.8–13.8)
Huijgen et al. (2012) [48]
• Event free survival in carriers of





Do et al. (2015) [15•]
• MI in carriers of non-synonymous
mutations LDLR gene vs. no non-
synonymous mutations LDLR gene
OR 4.2 (p=3×10^−11)
• MI in LDLR null mutation vs. no
null mutation
OR 13.0 (p=9×10^−5)
FH familial hypercholesterolemia, CVD cardiovascular disease, SMR
standardized mortality ratio, CI confidence interval, CAD coronary artery
disease, OR odds ratio, HR hazard ratio, p p value,MImyocardial infarc-
tion, LDLR LDL receptor
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comparison to monotherapy with simvastatin [55]. This unex-
pected result is likely related to the fact that the cIMT values at
the time of enrollment were not increased, and as a conse-
quence, a difference over time was less likely to be reached.
However, in the recently published IMPROVE-IT trial, car-
diovascular outcomes were evaluated in more than 18,000
patients who were hospitalized for an acute coronary syn-
drome. The results showed that a combination of ezetimibe
and statins resulted in additional LDL-C lowering and im-
proved cardiovascular outcomes [56].
Novel Therapies
As mentioned before, many individuals with FH are not able
to achieve sufficient reduction in LDL-C levels [50]. This
unmet need has driven the development of novel therapies
for further LDL-C lowering.
PCSK9 Inhibition
PCSK9 is a serine protease secreted by hepatocytes and is
involved in the degradation of the LDLR [10]. Monoclonal
antibodies against PCSK9 have been developed and result in
increased expression of the LDLR and therefore lowering of
LDL-C levels. Following phase 2 studies, PCSK9 inhibitors
alirocumab [57••] and evolocumab [58••] were compared to
placebo in subjects with heterozygous FH. Use of alirocumab
every 2 weeks resulted in LDL-C reduction of 67 % and sub-
cutaneous injections of evolocumab every 4 weeks resulted in
a 70 % lowering of LDL-C. Recently, the results of the
OSLER trial showed that evolocumab was efficacious and
safe [59].
CETP Inhibition
Cholesterylester transfer protein (CETP) is a protein that fa-
cilitates exchange of cholesteryl esters for triglycerides be-
tween and among HDL particles and apoB-containing lipo-
proteins (VLDL, intermediate-density protein (IDL), and LDL
particles) [60]. Blocking this transport by inhibiting CETP
results in an increase in HDL-C and apolipoprotein A1 and a
decrease in atherogenic lipoproteins such as LDL-C and Lp
(a) [61]. The recently published results of the REALIZE trial
showed that treatment with the CETP inhibitor anacetrapib for
1 year resulted in substantial reductions in LDL-C concentra-
tion [62]. The mechanism by which CETP reduction gives a
reduction in LDL-C is unknown. Rader and co-workers re-
cently showed that CETP inhibition by anacetrapib reduces
LDL-apoB-100 levels by increasing the rate of apoB-100 frac-
tional clearance and increasing affinity for the LDLR [63].
Whether CETP inhibition leads to a reduction in cardiovascu-
lar risks still has to be established in an outcome study.
Novel Therapies for the Treatment of Homozygous FH
Mipomersen is an antisense oligonucleotide that binds to
apoB messenger RNAwhich results in a decreased apoB syn-
thesis [64]. It is approved for treatment in patients with HoFH
in the USA but not in Europe. It has shown to lower plasma
LDL-C in 21 % in patients with HoFH [65] and 28 % in
patients with HeFH [66].
Lomitapide inhibits MTP at the hepatocytes and blocks the
transfer of triglycerides into VLDL in the liver and chylomi-
crons in the bowel [65]. Lomitapide is approved for treatment
of HoFH. LDL-C reductions of 50, 44, and 38%, respectively,
at 26, 56, and 78 weeks have been described [67].
Conclusion
FH is a common inherited disease which leads to premature
CVD and atherosclerosis, and early treatment is needed. FH is
widely underdiagnosed and LDL-C targets are often not
achieved so new therapies are being developed to overcome
this problem. This review gives an up to date overview of
clinically relevant information on FH.
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